New prescription drug labeling regulations and the demise of "the letter"

Obstet Gynecol. 2009 Sep;114(3):502-503. doi: 10.1097/AOG.0b013e3181b5bacc.

Author

Catherine Takacs Witkop¹

Affiliation

¹ Dr. Witkop is with Preventive Medicine and Obstetrics and Gynecology at the United States Air Force Academy, Colorado Springs, Colorado, and she is Assistant Professor, Obstetrics and Gynecology, at the Uniformed Services University of the Health Sciences, Bethesda, Maryland; e-mail: katika@aya.yale.edu.

PMID: 19701026
DOI: 10.1097/AOG.0b013e3181b5bacc

No abstract available

Publication types

Editorial

MeSH terms

Drug Labeling / legislation & jurisprudence*
Drug and Narcotic Control*
Female
Humans
Maternal-Fetal Exchange*
Pregnancy
Prescription Drugs*
Product Surveillance, Postmarketing
United States

Substances

Prescription Drugs